Avacta Group plc, the developer of Affimer biotherapeutics and reagents, has appointed BBI Solutions, part of BBI Group, to manufacture the saliva-based rapid SARS-CoV-2 antigen test that is being developed with Cytiva.    BBI Solutions is a global developer and manufacturer of raw materials and finished test products for the in-vitro diagnostics market, with manufacturing sites in five different countries, spanning four continents.    The manufacturing agreement between Avacta and BBI comprises...